Devonian Health Group Inc. Presents Study Findings on Thykamine™
Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation specializing in innovative solutions for inflammatory diseases, has unveiled remarkable results from its recent in vitro comparative study. This study focused on Thykamine™, demonstrating its superior anti-inflammatory potency compared to existing marketed agents.
Thykamine™ Compared to Existing Treatments
The study aimed to analyze the anti-inflammatory effects of Thykamine™ against products such as betamethasone valerate, clobetasol, crisaborole, 21-acetate hydrocortisone, pimecrolimus, and prednisone. The investigation involved treating factors such as lipopolysaccharide (LPS) stimulated U937 monocytic cells and assessing how much each agent inhibited various inflammatory cytokines.
Methods of Assessment
Cytokines play a significant role in autoimmune diseases, and during testing, researchers measured the inhibition of four specific cytokines: MCP-1, MIP-1?, MIP-1?, and RANTES. The inhibitions were calculated based on the reduction of cytokine activity after the addition of each treatment. An effective anti-inflammatory agent should notably reduce inflammation triggered by cytokines.
Findings Showcasing Thykamine™’s Potency
Against the backdrop of the other agents tested, Thykamine™ marked itself with significant higher inhibition rates for MCP-1 (by 28% to 136%; P< 0.009), MIP-1? (30% to 108%; P < 0.001), and MIP-1? (39% to 111%; P < 0.001). These results are pivotal, showcasing that its anti-inflammatory capacity is considerable, far surpassing existing treatments for various autoimmune ailments.
Expert Opinions on the Study's Implications
Commenting on the encouraging results, Dr. Louis Flamand, lead investigator, remarked on Thykamine™'s impressive properties as evidenced by the study and previous phase 2 clinical trials targeting conditions like ulcerative colitis and atopic dermatitis.
A New Perspective on Treatment Options
Dr. Lynde, a contributor to the study who previously investigated similar treatments, highlighted Thykamine™'s dual advantages of high potency alongside an optimal safety profile. He noted its potential use as a first-line treatment alternative, especially in light of increasing safety concerns tied to current therapies.
Broader Outlook from Clinical Experts
Dr. John Sampalis, a co-investigator of the study, shared his enthusiasm regarding Thykamine™. He noted that the drug may evolve into a primary treatment for several autoimmune disorders, due to its ability to reduce dependence on harsher treatments associated with significant side effects.
Future Research Development
In efforts to further validate these findings, study investigators expressed intentions to submit the results for publication in reputable peer-reviewed medical journals. This step could bolster the credibility of Thykamine™'s efficacy within the medical community.
About Thykamine™
Thykamine™, developed from Devonian's innovative SUPREX™ platform, represents a groundbreaking pharmaceutical advancement aimed at addressing inflammation-related health issues such as ulcerative colitis and atopic dermatitis. The extensive research backing its anti-inflammatory, antioxidative, and immunomodulatory benefits demonstrates the level of potential embedded within this product.
About Devonian Health Group Inc.
As a clinically focused pharmaceutical company, Devonian prioritizes the development of novel treatments targeting inflammatory autoimmune diseases. With a strong foundation of research exceeding 15 years, the company strives to create effective prescription drugs while adhering to regulatory standards that favor quicker and more efficient development processes.
Frequently Asked Questions
What is Thykamine™?
Thykamine™ is a pharmaceutical product developed by Devonian Health Group Inc. for treating conditions related to inflammation, such as ulcerative colitis and atopic dermatitis.
What did the recent study reveal about Thykamine™?
The study highlighted Thykamine™'s stronger anti-inflammatory potency compared to traditional agents, indicating its potential as a first-line treatment option for autoimmune diseases.
Who conducted the study on Thykamine™?
The study was carried out by researchers at Université Laval in collaboration with experts from McGill University and other distinguished institutions.
What are the key cytokines measured in the study?
The study assessed MCP-1, MIP-1?, MIP-1?, and RANTES as key inflammatory markers impacted by Thykamine™ and other agents.
What is Devonian’s mission?
Devonian Health Group Inc. aims to develop innovative pharmaceutical solutions that address unmet medical needs in the field of autoimmune inflammatory conditions.
